Market Cap (In USD)
2.76 Billion
Revenue (In USD)
12.76 Million
Net Income (In USD)
-176.93 Million
Avg. Volume
344.96 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 10.5-27.29
- PE
- -
- EPS
- -
- Beta Value
- -0.001
- ISIN
- NL00150012L7
- CUSIP
- -
- CIK
- 1936258
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Michael Harvey Davidson FACC, Facp., M.D.
- Employee Count
- -
- Website
- https://www.newamsterdampharma.com
- Ipo Date
- 2021-02-09
- Details
- NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
More Stocks
-
THRM
-
FSM
-
BCSAU
-
AGR
-
225570Nat Games Co.,Ltd.
225570
-
VLVCYVolvo Car AB (publ.)
VLVCY
-
6257
-
COLUMColumbus A/S
COLUM